E
Edward W. Roberts
Researcher at University of California, San Francisco
Publications - 26
Citations - 8301
Edward W. Roberts is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 16, co-authored 22 publications receiving 5307 citations. Previous affiliations of Edward W. Roberts include University of Cambridge.
Papers
More filters
Journal ArticleDOI
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies,Edward W. Roberts,Kelly Kersten,Vincent Chan,Douglas F. Fearon,Miriam Merad,Lisa M. Coussens,Dmitry I. Gabrilovich,Suzanne Ostrand-Rosenberg,Suzanne Ostrand-Rosenberg,Catherine C. Hedrick,Robert H. Vonderheide,Mikael J. Pittet,Rakesh K. Jain,Weiping Zou,T. Kevin Howcroft,Elisa C. Woodhouse,Robert A. Weinberg,Matthew F. Krummel +18 more
TL;DR: By parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.
Journal ArticleDOI
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig,James O. Jones,Matthew Kraman,Richard J.B. Wells,Andrew Deonarine,Derek S. Chan,Claire M. Connell,Edward W. Roberts,Qi Zhao,Otavia L. Caballero,Sarah A. Teichmann,Tobias Janowitz,Duncan I. Jodrell,David A. Tuveson,Douglas T. Fearon +14 more
TL;DR: A single protein, CXCL12, from a single stromal cell type, the FAP+ CAF, may direct tumor immune evasion in a model of human PDA, which permitted the analysis of why immunotherapy is ineffective in this human disease.
Journal ArticleDOI
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Matthew Kraman,Paul J. Bambrough,James N. Arnold,Edward W. Roberts,Lukasz Magiera,James O. Jones,Aarthi Gopinathan,David A. Tuveson,Douglas T. Fearon +8 more
TL;DR: Findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Journal ArticleDOI
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts,Miranda Broz,Mikhail Binnewies,Mark B. Headley,Amanda E. Nelson,Denise M. Wolf,Tsuneyasu Kaisho,Dusan Bogunovic,Nina Bhardwaj,Matthew F. Krummel +9 more
TL;DR: This work identifies an ongoing pathway to T cell priming, which should be harnessed for tumor therapies, and CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and better clinical outcomes.
Journal ArticleDOI
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Melody A. Swartz,Noriho Iida,Edward W. Roberts,Sabina Sangaletti,Melissa H. Wong,Fiona E. Yull,Lisa M. Coussens,Yves A. DeClerck +7 more
TL;DR: The tumor microenvironment (TME) consists of cells, soluble factors, signaling molecules, extracellular matrix, and mechanical cues that can promote neoplastic transformation, support tumor growth and invasion, protect the tumor from host immunity, foster therapeutic resistance, and provide niches for dormant metastases to thrive.